INDEPENDENT ANTI-DOPING REFERENCE2026 · CHECKED 08 NOV 2027 PUBLISHED ↗
WADAFUK!?
Source-checked educational research

Trestolone.

S1
Source-checked educational research

Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.

REGULATORY SUMMARY2026 LIST

Prohibited at all times

Trestolone is covered by S1.1 of the effective 2026 WADA List and is prohibited in and out of competition. S1.1 applies to exogenous administration; its coverage is not limited to the named examples and includes relevant esters. [3]

S1.1; 2026 List, printed pages 5–6 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.

EVIDENCE / 01

Human contraceptive research

A study of MENT acetate implants in 35 male volunteers reported suppression of reproductive hormones and sperm production, with variable responses. Changes in hematocrit, hemoglobin and other laboratory measures were also observed. [1]

Limits of this evidence
  • Study findings concern the acetate implant formulation. They do not establish reliable contraception, current approval or safety of unregulated trestolone products.
EVIDENCE / 02

List year

The 2026 List is the effective edition on this review date. The checked 2027 S1 text showed no change, but the 2027 edition does not take effect until 1 January 2027. [3] [4] [2]

Limits of this evidence
  • Consult the official edition and responsible anti-doping organization for consequential decisions. This reference does not provide medical advice, a TUE decision, product certification or individual clearance.

What remains uncertain

  • This is a targeted source check, not a systematic review or independent clinical/regulatory sign-off. Uncited draft claims remain unpublished.
  • Chemical registry identifiers, every alias and jurisdiction-specific product availability have not been exhaustively reconciled.
TRACEABILITY

Check the sources.

These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.

  1. A clinical trial of 7 alpha-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men. ↗Accessed 2026-11-10 · indexed original abstract read via Europe PMC MED record; full article not reviewed

    Abstract; PMID 14602755

  2. 2027 Prohibited List resource page ↗Accessed 2026-11-10 · relevant primary-source text read · FUTURE 2027 SOURCE

    Resource description and effective date

  3. WADA 2026 Prohibited List ↗Accessed 2026-11-10 · relevant primary-source text read

    Introduction and S1, printed pages 3, 5–6

  4. WADA 2027 Prohibited List, currently linked English file ↗Accessed 2026-11-10 · relevant primary-source text read · FUTURE 2027 SOURCE

    Cover and S1, printed pages 1, 5–6

Before acting on this information

Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.

Something wrong? Prepare a correction draft ↗